DMEM, high glucose, pyruvate
El producto real puede variar
Gibco™

DMEM, high glucose, pyruvate

DMEM (Dulbecco's Modified Eagle Medium) is a widely used basal medium for supporting the growth of many different mammalian cells.
Have Questions?
Número de catálogoCantidad
41966052
también denominado 41966-052
10 x 500 mL
Número de catálogo 41966052
también denominado 41966-052
Precio (MXN)
-
Cantidad:
10 x 500 mL
Customize this product

DMEM (Dulbecco's Modified Eagle Medium) is a widely used basal medium for supporting the growth of many different mammalian cells. Cells successfully cultured in DMEM include primary fibroblasts, neurons, glial cells, HUVECs, and smooth muscle cells, as well as cell lines such as HeLa, 293, Cos-7, and PC-12. We offer a variety of DMEM modifications for a range of cell culture applications. Find the right formulation using the media selector tool.

This DMEM is modified as follows:

With: High Glucose, L-glutamine, Phenol Red, Sodium Pyruvate

Without: HEPES

The complete formulation is available.

Using DMEM

DMEM is unique from other media as it contains 4 times the concentration of amino acids and vitamins than the original Eagle's Minimal Essential Medium. DMEM was originally formulated with low glucose (1 g/L) and sodium pyruvate, but is often used with higher glucose levels, with or without sodium pyruvate. DMEM contains no proteins, lipids, or growth factors. Therefore, DMEM requires supplementation, commonly with 10% Fetal Bovine Serum (FBS). DMEM uses a sodium bicarbonate buffer system (3.7 g/L), and therefore requires a 5–10% CO2 environment to maintain physiological pH.

For Research Use or Further Manufacturing. Not for diagnostic use or direct administration into humans or animals.
Especificaciones
Línea de célulasHeLa, 293, Cos-7 y PC-12
Tipo de célulaFibroblastos primarios, neuronas, células gliales, HUVEC y células de músculo liso
Concentración1X
Entorno de cultivoCO2
Para utilizar con (aplicación)Mammalian Cell Culture
FormatoBottles
Concentración de glucosa4500 mg/L
Calidad de fabricacióncGMP-compliant under the ISO 13485 standard
Línea de productosGibco
Tipo de productoDMEM (Dulbecco's Modified Eagle Medium)
Cantidad10 x 500 mL
Duración de almacenamiento12 Months From Date of Manufacture
Condiciones de envíoAmbiente
ClasificaciónAnimal Origin-free
Culture TypeMammalian Cell Culture
FormularioLíquido
Serum LevelStandard Serum Supplementation
EsterilidadEstéril con filtro
Sterilization MethodSterile-filtered
Con aditivosAlto contenido en glucosa, Glutamina, Piruvato sódico, Rojo de fenol
Sin aditivosSin Ácido 4-(2-hidroxietil)piperazin-1-iletanosulfónico (HEPES)
pH7.0 to 7.4
Unit SizeEach
Contenido y almacenamiento
Condiciones de almacenamiento: De 2 a 8 °C. Proteger de la luz
Condiciones de envío: Ambiente
Vida útil: 12 meses a partir de la fecha de fabricación

Preguntas frecuentes

What is the manganese concentration in DMEM? Do you offer manganese-free DMEM?

Manganese is not present in the formulation of our catalog DMEM media products.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

Citations & References (2)

Citations & References
Abstract
Agonism and antagonism at the insulin receptor.
Authors:Knudsen L, Hansen BF, Jensen P, Pedersen TÅ, Vestergaard K, Schäffer L, Blagoev B, Oleksiewicz MB, Kiselyov VV, De Meyts P,
Journal:PLoS One
PubMed ID:23300584
'Insulin can trigger metabolic as well as mitogenic effects, the latter being pharmaceutically undesirable. An understanding of the structure/function relationships between insulin receptor (IR) binding and mitogenic/metabolic signalling would greatly facilitate the preclinical development of new insulin analogues. The occurrence of ligand agonism and antagonism is well described for G ... More
Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.
Authors:Jones JL, Anderson JM, Phuah CL, Fox EJ, Selmaj K, Margolin D, Lake SL, Palmer J, Thompson SJ, Wilkins A, Webber DJ, Compston DA, Coles AJ
Journal:Brain
PubMed ID:20659956
Treatment of early relapsing-remitting multiple sclerosis with the lymphocyte-depleting humanized monoclonal antibody alemtuzumab (Campath [registered trade mark]) significantly reduced the risk of relapse and accumulation of disability compared with interferon ß-1a in a phase 2 trial [Coles et al., (Alemtuzumab vs. interferon ß-1a in early multiple sclerosis. N Engl J ... More